T. Kishimoto
Immunology · 2000–2019
A researcher in the Science corpus: 15 papers; trusts 2 researchers and is trusted by 24 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 84 citations into it; #126 of 2,160 by trust here, #433 by citations
- Rheumatology — 22 citations into it; #101 of 221 by trust here, #26 by citations
Whom T. Kishimoto trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts T. Kishimoto overall
- Markus F. Neurath
- S. Rose‐John
- Mi-Young Kim
- S. Finotto
- Toshio Tanaka
- D. Schmidt-Arras
- D. Campbell
- Thordur Oskarsson
- Simon A. Jones
- D. Schaue
Papers from T. Kishimoto's perspective
Ordered by how strongly the researchers T. Kishimoto trusts endorse each paper. Same corpus, a different order for every researcher.
- Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system (Nature Immunology)
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells (Nature)
- Humanized anti-interleukin-6 receptor antibody
- Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. (Arthritis & Rheumatism)
- Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
- A novel inflammation‐related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate (Cancer Science)
- IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. (Journal of Clinical Investigation)
- Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages (Nature Immunology)
- Ido expression by dendritic cells: tolerance and tryptophan catabolism (Nature reviews. Immunology)
- T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. (Immunity)
Their papers
- TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling (2004) — 676 citations
- Targeting Interleukin-6 Signaling in Clinic. (2019) — 744 citations
- Immunotherapeutic implications of IL-6 blockade for cytokine storm. (2016) — 638 citations
- IL-6 in inflammation, immunity, and disease. (2014) — 4,456 citations
- Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism (2010) — 687 citations
- IL‐6: Regulator of Treg/Th17 balance (2010) — 1,589 citations
- IL-6: from its discovery to clinical applications. (2010) — 830 citations
- Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. (2008) — 738 citations
- Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab (2007) — 729 citations
- Interleukin 6: from bench to bedside (2006) — 625 citations
- Interleukin-6: from basic science to medicine--40 years in immunology. (2005) — 1,067 citations
- Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. (2004) — 786 citations
- A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. (2004) — 647 citations
- SOCS-1 participates in negative regulation of LPS responses. (2002) — 708 citations
- Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo (2000) — 1,336 citations